Enovis Corp (ENOV) Receives Buy Rating from Freedom Capital
Freedom Capital Markets initiates coverage on Enovis Corp with a Buy rating.
Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 7,367 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company also operates a Enovis Growth eXcellence business system (EGX).
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Enovis Corp.
Last Updated: Dec 24, 2025, 12:13 AM · Source: Finnhub.io
Freedom Capital Markets initiates coverage on Enovis Corp with a Buy rating.
Insider John Kleckner buys 12,302 shares of Enovis Corp (ENOV) at $30.32 each, totaling $373K.
Enovis Corp (ENOV) exceeded earnings expectations in Q3 2025.